- Home
- HSBC vs KZR Comparison
HSBC vs KZR Comparison
Compare HSBC & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HSBC | KZR |
|---|---|---|
| Founded | 1865 | 2015 |
| Country | United Kingdom | United States |
| Employees | 209000 | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.2B | 54.2M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HSBC | KZR |
|---|---|---|
| Price | $88.45 | $7.29 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.5M | 88.7K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.18% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.95 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $94.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $58.39 | $3.53 |
| 52 Week High | $94.80 | $7.55 |
Technical Indicators
Market Signals| Indicator | HSBC | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 54.64 |
| Support Level | $84.57 | $7.25 |
| Resistance Level | $92.06 | $7.47 |
| Average True Range (ATR) | 1.44 | 0.11 |
| MACD | -0.31 | -0.02 |
| Stochastic Oscillator | 42.64 | 37.50 |
Price Performance
Historical ComparisonAbout HSBC HSBC Holdings plc.
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and over 40 million customers worldwide. It operates in more than 50 countries with over 200,000 full-time staff. Hong Kong and the United Kingdom are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.